7FIT is a founder-controlled Polish supplement compounder whose rapid profit growth, proprietary-brand shift, and discounted micro-cap valuation create asymmetric upside—if working capital and regulatory risks remain contained.
7FIT S.A. (formerly operating as Triceps.pl Spółka Akcyjna) is a Poland-based developer, manufacturer, and distributor of sports nutrition, dietary supplements, and healthy food products.[1, 2] Operating out of its corporate headquarters and primary fulfillment center in Stanowice, Poland, the enterprise has carved out a high-growth niche within the Central and Eastern European (CEE) wellness market.[1, 3, 4] The business is centered around a successful dual-brand strategy: developing its proprietary flagship brand, 7Nutrition, while maintaining a broad product catalog of distributed third-party brands.[4, 5]
The commercial model of 7FIT S.A. utilizes an omni-channel distribution architecture to generate revenue.[1, 2] These channels are structured as follows:
| Distribution Channel | Operational Mechanism & Customer Focus |
|---|---|
| B2B Wholesale Platform | A proprietary digital purchasing portal serving gyms, physical fitness stores, independent pharmacies, and regional sub-distributors across Europe.[1, 4, 6] |
| Direct-to-Consumer (DTC) | Integrated e-commerce webstores, including triceps.pl and 7nutrition.eu, designed for direct retail customer acquisition.[1, 7, 8] |
| Physical Retail Footprint | A flagship brick-and-mortar retail location at ul. Bartłomieja Strachowskiego 28A in Wrocław, alongside a network of regional franchise partners.[2, 3, 4] |
┌──────────────────────────────────────────┐
│ 7FIT S.A. │
│ Omni-Channel Model │
└────────────────────┬─────────────────────┘
│
┌───────────────────┼───────────────────┐
▼ ▼ ▼
┌─────────────────┐ ┌─────────────────┐ ┌─────────────────┐
│ B2B Wholesale │ │ DTC E-Commerce │ │ Physical Retail │
│ Gyms, Stores │ │ Web Platforms │ │ Flagship Store, │
│ & Distributors │ │ & Direct Ad │ │ Franchises │
│ [1, 6]│ │ [1, 7] │ │ [3, 4]│
└─────────────────┘ └─────────────────┘ └─────────────────┘
The company's revenue generation is geographically centered in Poland [3, 4], with an expanding international footprint supported by dedicated local representations in Great Britain, Ireland, Germany, Spain, Denmark, Slovakia, and France.[6] The customer base ranges from elite professional athletes and fitness enthusiasts to mainstream, health-conscious retail consumers.[1, 7, 8]
The company's primary corporate profile parameters are summarized below:
| Parameter | Value / Detail |
|---|---|
| Headquarters | Stanowice (Oława Municipality), Poland [3, 4] |
| Exchange Ticker | 7FT (Warsaw NewConnect Exchange) [3, 9, 10, 11] |
| Shares Outstanding | 1,792,500 Shares [12, 13, 14] |
| Primary Proprietary Brand | 7Nutrition [1, 5] |
| Distributed External Brands | Formotiva, RealPharm, Lab One, Activlab [5] |
| Full-Time Employees | 21 Employees (as of mid-2026) [5, 11] |
The business has established a clean shareholder structure that aligns management with outside investors, with founders and key executives controlling a significant majority of the voting rights:
| Shareholder | Share Count | Equity Stake (%) | Voting Stake (%) |
|---|---|---|---|
| Michał Wasilewski | 914,175 | 51.00% | 65.49% |
| Arkadiusz Bała | 350,040 | 19.53% | 13.75% |
| Sone sp. z o.o. (with SO International) | 176,075 | 9.82% | 6.92% |
| Michał Kopiczyński | 139,000 | 7.75% | 5.46% |
| Free Float | 213,210 | 11.89% | 8.38% |
| Total | 1,792,500 | 100.00% | 100.00% [2, 6] |
Customers choose 7FIT S.A. over competitors because of its clean product formulations, competitive pricing, high stock availability, and fast, automated order fulfillment via its integrated B2B and DTC platforms.[6, 8]
7FIT S.A. operates in a highly dynamic sector driven by rising consumer health awareness, interest in active lifestyles, and a growing emphasis on preventive wellness.[15]
The company's growth strategy centers on three main revenue drivers:
The company's competitive moat is based on localized brand equity, distributor switching costs, and cost advantages:
The total addressable market (TAM) for dietary supplements is expanding rapidly. Industry research indicates that up to 75% of adult Poles regularly consume dietary supplements, with e-commerce accounting for an increasing share of overall volume.[17] The broader supplement market is projected to grow over the medium term, supported by post-pandemic health awareness, rising consumer spending on proactive health, and the growing popularity of active lifestyles.[15] Within this market, specialized sub-segments are growing even faster: probiotics are expanding at a compound annual growth rate (CAGR) of approximately 14%, while plant proteins and amino acids are growing at a 12.2% CAGR.[18]
│
├─►
├─►
└─►
7FIT S.A. operates in a highly fragmented competitive landscape.[13, 14] The market can be divided into two main categories:
This hybrid positioning has allowed 7FIT S.A. to gain market share, supported by a 30.47% year-over-year revenue increase in 2025 and a further 60.69% acceleration in Q1 2026.[4, 13]
7FIT S.A. has demonstrated a sharp acceleration in both top-line revenue and net profitability over the past several quarters.[4, 13] The most recent financial reporting period is the first quarter of 2026, which was announced on May 15, 2026.[13, 16]
In Q1 2026, 7FIT S.A. delivered strong operating results:
A direct comparison of the latest Q1 results reveals the rapid expansion of the company's operating leverage:
| Financial Metric (Q1 Period) | Q1 2025 (PLN) | Q1 2026 (PLN) | Year-over-Year Change (%) |
|---|---|---|---|
| Sales Revenue | 8,354,000 | 13,424,000 | +60.69% |
| Operating Profit (EBIT) | 875,000 | 1,940,000 | +121.71% |
| Pre-tax Profit | 825,000 | 1,944,000 | +135.64% |
| Net Income | 662,000 | 1,565,000 | +136.40% |
| Total Assets | 14,905,000 | 19,367,000 | +29.94% |
| Shareholders' Equity | 7,038,000 | 10,575,000 | +50.26% [13] |
Because 7FIT S.A. is a micro-cap company traded on the NewConnect alternative trading system (rather than the GPW Main Market), it has limited institutional analyst coverage.[11, 19] Consequently, there are no formal, compiled consensus analyst expectations (such as explicit revenue or EPS quarterly targets) against which to measure "beats" or "misses".[11, 19] However, the absolute growth trajectory represents a clear outperformance compared to the broader retail and specialty distribution peer group.[13]
Management did not issue formal quantitative guidance changes during the latest earnings release, though corporate communications consistently highlighted a commitment to expanding export channels and growing the B2B wholesale platform.[4, 6] In his letter to shareholders accompanying the 2025 annual results published on May 29, 2026, the President of the Board, Arkadiusz Bała, emphasized that prior investments in warehouse infrastructure and product catalog diversification were successfully driving operational margins.[4]
This strong performance has had a clear impact on market dynamics. The stock price rose to multi-year highs, reaching a 52-week peak of 26.60 PLN on May 19, 2026, shortly after the Q1 results were released.[9, 13] While institutional price targets are unavailable due to the lack of formal coverage, the market has re-rated the stock, which gained 118.80% year-to-date and 281.52% over the trailing 12 months as of June 2026.[13]
To provide historical context, a summary of the audited annual results for 2025 and 2024 highlights the underlying drivers of the business model [4]:
| Metric | FY 2024 (PLN) | FY 2025 (PLN) | Year-over-Year Change (%) |
|---|---|---|---|
| Net Revenue from Sales | 27,094,434.09 | 35,348,337.71 | +30.47% [4] |
| Gross Profit from Sales | 1,664,323.07 | 3,647,659.89 | +119.17% [4] |
| Operating Profit (EBIT) | 1,536,690.57 | 3,582,413.99 | +133.13% [4] |
| Net Income | 1,044,582.13 | 2,829,955.67 | +171.00% [4] |
| Depreciation | 241,033.11 | 317,598.35 | +31.77% [4] |
| EBITDA | 1,777,723.68 | 3,900,012.34 | +119.38% [4, 5] |
Balance sheet metrics as of December 31, 2025, show a highly liquid, though working-capital-intensive, structure [4]:
The company's strong execution has supported a solid record of dividend payments. On May 29, 2026, the Board recommended a dividend of 0.31 PLN per share for the fiscal year 2025, representing a 182% increase over the previous year.[19, 20, 21] The historical dividend trajectory reflects the company's consistent capital return profile:
| Fiscal Year | Dividend per Share (PLN) | Total Payout (PLN) | Dividend Yield (%) | Ex-Dividend Date | Payment Date |
|---|---|---|---|---|---|
| 2025 | 0.31 | 555,675 | 1.29% | Jul 08, 2026 | Jul 17, 2026 [9, 19, 21] |
| 2024 | 0.11 | 197,180 | 1.42% | Jul 09, 2025 | Jul 18, 2025 [19, 20, 22] |
| 2023 | 0.14 | 250,95 | 1.30% | Aug 21, 2024 | Aug 28, 2024 [20, 22] |
| 2022 | 0.08 | 143,40 | 1.24% | Jun 30, 2023 | Jul 10, 2023 [20, 22] |
| 2021 | 0.10 | 179,25 | 2.40% | Aug 02, 2022 | Aug 10, 2022 [20, 22] |
| 2020 | 0.09 | 161,33 | 1.68% | Aug 02, 2021 | Aug 16, 2021 [20, 22] |
| 2019 | 0.06 | 107,55 | 1.84% | Aug 26, 2020 | Sep 22, 2020 [20, 22] |
Based on a trading price of 24.00 PLN and 1,792,500 shares outstanding, the company has an equity market capitalization of 43.02 million PLN.[9, 11, 12] The primary valuation multiples are as follows:
The key financial drivers for valuation include a 5-year sales CAGR of approximately 15% and ROE of 35.30% to 44.10%.[7, 13] At a P/E multiple of ~11.5x, the market is pricing 7FIT S.A. as a mature, low-growth distributor rather than a high-growth brand owner.[11, 12] This multiple compression is primarily due to its listing on the NewConnect alternative exchange, which suffers from low trading volumes, and its high non-cash earnings profile (26% accrual ratio).[9, 19] If the company maintains double-digit sales growth while maintaining net margins near 10%, operational cash generation should improve, supporting potential multiple expansion.[13, 19]
Investing in 7FIT S.A. carries several structural, operational, and regulatory risks that should be carefully evaluated:
The business operates with a very lean corporate structure, employing only 21 people as of mid-2026.[5, 11] This introduces key-person dependencies, particularly on the founders, Michał Wasilewski and Arkadiusz Bała, who manage primary distributor relationships and brand development.[5, 12] Key-person risk is amplified by the company's international expansion plans, as managing multiple foreign distributor agreements without regional sales teams could strain executive capacity.[4, 6]
The sports nutrition and dietary supplement industry has very low barriers to entry. 7FIT S.A. has limited intellectual property protection on standard powder formulations, making it highly dependent on brand marketing and consumer perception.[1] Larger, well-capitalized food conglomerates or retail chains could develop competing private-label supplement brands, pressuring margins and reducing shelf space.[13, 14]
While e-commerce sales are growing, 7FIT S.A. remains highly dependent on its B2B wholesale platform and regional retail distributors.[1, 6] The loss of a major wholesale distributor in Poland or an international market could cause immediate revenue declines.[4, 6]
The regulatory environment for dietary supplements in Poland is tightening significantly:
Because 7FIT S.A. sells complex formulations (including boosters and stimulants), any sudden ban on specific ingredients by Polish or European food safety authorities could require costly product recalls and inventory write-offs.[5]
Regulatory Risk Transmission Chain
Tightening Regulations (2026) ──► Strict Labeling & Ad Bans [23]
──► High Fines (100x Avg Salary) [23]
──► Potential Ingredient Bans & Recalls [5]
Despite generating 2.83 million PLN in net income in 2025, the company's cash position fell from 668,868 PLN to 389,410 PLN.[4] This cash drain was driven by working capital expansion, with inventories growing to 9.69 million PLN and receivables increasing to 3.88 million PLN.[4] 7FIT S.A. has been flagged for a high level of non-cash earnings (accrual ratio of 26%).[19] If the company fails to efficiently convert receivables and inventory into cash, it could face liquidity constraints, potentially forcing it to limit growth initiatives or cut its dividend.[4, 19]
The business is highly sensitive to input cost inflation, particularly for key raw materials like whey protein, creatine, and packaging materials. Since sports supplements are discretionary items, high inflation or an economic downturn in Poland could lead consumers to cut back on discretionary wellness products, negatively affecting volumes.
The 5-year scenario analysis (projecting out to 2031) assumes a baseline of 1,792,500 shares outstanding.[3, 4, 12] It is built on the current share price of 24.00 PLN [9], representing a starting market capitalization of 43.02 million PLN.[11]
This scenario assumes that 7FIT S.A. maintains its solid position in Poland while achieving moderate success in its international expansion.[4, 6]
This scenario assumes that the company's international expansion accelerates rapidly, and the e-commerce channel grows into a major driver of high-margin retail sales.[1, 4, 6]
This scenario assumes that 7FIT S.A. encounters severe regulatory headwinds in Poland, failed international expansion, and margin compression due to rising raw material costs.[4, 23]
The modeled trajectory displays the projected annual share price progression for each of the three defined operating scenarios over the next five years:
| Scenario | Year 0 (Current) | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 (Exit) |
|---|---|---|---|---|---|---|
| High Case (25% Prob) | 24.00 | 31.50 | 41.34 | 54.26 | 71.21 | 99.30 |
| Base Case (55% Prob) | 24.00 | 26.85 | 30.04 | 33.62 | 37.62 | 42.84 |
| Low Case (20% Prob) | 24.00 | 20.20 | 17.00 | 14.31 | 12.04 | 10.08 |
The probability-weighted share price target is calculated as:
$\text{Weighted Price Target} = (42.84 \times 0.55) + (99.30 \times 0.25) + (10.08 \times 0.20) = 50.40 \text{ PLN}$
This implies a 110.0% total return and an annualized return of 16.0% over 5 years.
| Scenario | Revenue / key scale metric in Year 5 | Margin / earnings assumption | Valuation multiple assumption | Current share price | Implied future share price | 5-year total return | Annualized return | Probability |
|---|---|---|---|---|---|---|---|---|
| High Case | 107.88M PLN [4] | 11.0% Net Margin / 11.87M PLN [4] | 15x P/E [13, 19] | 24.00 PLN [9] | 99.30 PLN [3, 4] | +313.8% | +32.8% | 25% |
| Base Case | 71.10M PLN [4] | 9.0% Net Margin / 6.40M PLN [4] | 12x P/E [13, 19] | 24.00 PLN [9] | 42.84 PLN [3, 4] | +78.5% | +12.3% | 55% |
| Low Case | 45.12M PLN [4] | 5.0% Net Margin / 2.26M PLN [4] | 8x P/E [13, 19] | 24.00 PLN [9] | 10.08 PLN [3, 4] | -58.0% | -16.1% | 20% |
| Weighted | 70.25M PLN | 8.6% Net Margin / 6.07M PLN | 11.4x P/E | 24.00 PLN | 50.40 PLN | +110.0% | +16.0% | 100% |
ASYMMETRIC GROWTH POTENTIAL
Rating evaluation scores on a scale of 1–10:
Qualitative Scorecard Ratings (Scale 1-10)
Management Alignment ────────── 8
Revenue Quality ─────────────── 6
Market Position ─────────────── 7
Growth Outlook ──────────────── 8
Financial Health ────────────── 7
Business Viability ──────────── 6
Capital Allocation ──────────── 8
Analyst Sentiment ───────────── 5
Profitability ───────────────── 8
Track Record ────────────────── 7
---------------------------------
Blended Score: 7.0 / 10
The founding management team maintains significant equity ownership: Michał Wasilewski holds 51.00% of outstanding shares (65.49% of voting rights) and Arkadiusz Bała holds 19.53% (13.75% of voting rights).[2, 6] Insider activity shows they are long-term holders, and there has been no excessive dilution, aligning management’s interests with minority shareholders.[3, 4]
The company benefits from recurring B2B wholesale revenues and immediate cash generation through its DTC e-commerce channels.[1, 6] However, the high non-cash accrual ratio of 26% and working capital tied up in inventory and receivables constrain overall revenue quality.[4, 19]
7FIT S.A.’s flagship brand, 7Nutrition, is a well-established player in the specialty Polish sports nutrition channel.[1, 16] While the company is small compared to major retail giants, its rapid growth—30.47% in FY 2025 and 60.69% in Q1 2026—suggests it is successfully gaining market share.[4, 13]
The company’s growth outlook is supported by favorable consumer trends in dietary supplement use (75% of adult Poles regularly consume supplements) and strong growth in sub-segments like probiotics and nootropics.[17, 18] Expanding international B2B relationships provides a clear path for continued growth.[4, 6]
The company maintains a strong balance sheet with an Altman Z-score in the AAA safety range (9.66) and interest coverage of 27.45x.[7, 13, 16] However, the cash position declined in 2025 due to working capital requirements, which remains a key metric to monitor.[4]
Low barriers to entry in the industry make 7FIT S.A. highly dependent on maintaining consumer brand loyalty.[1] Tightening regulations in Poland, which restrict advertising claims and impose substantial fines, present a significant risk to long-term viability.[23]
Management has demonstrated a highly disciplined approach to capital allocation, delivering a 44.10% ROE and 31.42% ROIC.[7] The company has a consistent history of dividend payments, proposing 0.31 PLN per share for 2025 (a 182% increase over 2024), while maintaining a conservative payout ratio.[19, 20, 21]
Due to its NewConnect listing and micro-cap status, the company has virtually no sell-side coverage.[11, 19] While this lack of coverage creates a potential mispricing opportunity, it also means the stock lacks institutional support.[11, 19]
Profitability has improved significantly, with net margins rising from 4.2% in previous years to 8.0% in FY 2025 and 11.6% in Q1 2026.[4, 13, 19] High ROE and ROA metrics demonstrate excellent operating leverage.[7, 13]
Since its founding in 2006 and listing in 2012, the company has built a solid operational track record, delivering a 316% total return to shareholders over the past three years.[1, 3, 19]
This analysis indicates that 7FIT S.A. is a fundamentally strong, founder-led business experiencing rapid growth, but it is constrained by a competitive industry structure and inventory-heavy working capital requirements.[2, 4]
HIGH-ALIGNMENT NICHE PLAYER
The investment thesis for 7FIT S.A. rests on its ongoing transition from a regional supplement distributor to a high-margin proprietary brand owner.[1, 4, 5] This strategic shift has driven operational scale, as seen in the company's strong Q1 2026 results (60.69% revenue growth and 136.40% net income growth).[13]
Key catalysts that could drive a re-rating of the stock include:
However, these opportunities must be balanced against key risks:
At an implied trading multiple of roughly 11.5x TTM P/E, 7FIT S.A. is currently valued at a discount to its growth potential, primarily due to exchange-specific liquidity constraints.[9, 13, 19] If the company successfully converts its book earnings into free cash flow while maintaining double-digit sales growth, it has significant potential for valuation multiple expansion.[4, 19]
NARROW-MOAT GROWTH STORY
The stock price of 7FIT S.A. has exhibited strong upward momentum over the past year, gaining 247.83%.[5, 11] It is currently trading significantly above its 200-day simple moving average (SMA) of 13.64 PLN, reflecting strong market appreciation of its underlying financial performance.[13, 14]
7FIT S.A. Price vs. 200-Day SMA
Current Price: ─────── 24.00 PLN [9]
200-Day SMA: ─── 13.64 PLN [14]
Although some technical indicators (such as RSI and Williams %R) suggested overbought conditions in late May 2026, the stock has since consolidated near the 24.00 PLN range, digesting its massive run-up to a 52-week high of 26.60 PLN.[9, 13] The short-term outlook remains neutral-to-bullish, as the stock is well-supported near its current level, with investors awaiting the Q2 2026 financial results scheduled for publication on August 14, 2026.[13]
BULLISH CONSOLIDATION
View 7FT.WA,0P0000WAHL,1 (7FT.WA) stock page
Loading the interactive version of this report…